Goldman Sachs
NUTX

Goldman Sachs’s Nutex Health NUTX Stock Holding History

Goldman Sachs’s Portfolio NUTX Stock Details NUTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.21M Buy
33,795
+14,508
+75% +$1.78M ﹤0.01% 4115
2025
Q4 		$3.18M Sell
19,287
-10,160
-35% -$1.35M ﹤0.01% 4177
2025
Q3 		$3.04M Buy
29,447
+18,397
+166% +$1.8M ﹤0.01% 4100
2025
Q2 		$1.38M Sell
11,050
-7,069
-39% -$913K ﹤0.01% 4468
2025
Q1 		$852K Buy
18,119
+2,748
+18% +$134K ﹤0.01% 4815
2024
Q4 		$487K Buy
+15,371
New +$438K ﹤0.01% 5268
2024
Q1 		– Sell
-263
Closed -$7.09K – 5774
2023
Q4 		$7.09K Sell
263
-1,689
-87% -$52.7K ﹤0.01% 5502
2023
Q3 		$59.3K Sell
1,952
-4,055
-68% -$196K ﹤0.01% 5257
2023
Q2 		$380K Buy
6,007
+5,314
+767% +$456K ﹤0.01% 4882
2023
Q1 		$105K Sell
693
-41
-6% -$8.3K ﹤0.01% 5452
2022
Q4 		$209K Buy
734
+356
+94% +$68.4K ﹤0.01% 5283
2022
Q3 		$85K Sell
378
-6,313
-94% -$2.68M ﹤0.01% 5722
2022
Q2 		$3.24M Buy
+6,691
New +$7.89M ﹤0.01% 3602

Other funds holding NUTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.37B AUM 36.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WC
Winmill & Co Rochester, New York $347M AUM 37.48% 1-Year Est. Return

Goldman Sachs's NUTX Position: Q1 2026 in Review

Goldman Sachs increased its Nutex Health (NUTX) stake by 75% in Q1 2026, buying an estimated $1.78M and bringing the position to 33,795 shares worth $3.21M. The position accounts for ﹤0.01% of the portfolio, ranked #4115.

Goldman Sachs first reported a position in NUTX in Q2 2022 and has held it in 13 quarters since. The position peaked at $3.24M in Q2 2022. 129 funds tracked by Wall St. Rank hold NUTX as of Q1 2026.

  • Goldman Sachs held 33,795 shares of Nutex Health worth $3.21M as of Q1 2026.
  • Goldman Sachs bought 14,508 Nutex Health shares in Q1 2026, an estimated $1.78M.
  • Nutex Health made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4115 holding.
  • Goldman Sachs first reported a position in Nutex Health in Q2 2022 and has held it in 13 quarters since.
  • Goldman Sachs's Nutex Health position peaked at $3.24M in Q2 2022.
  • 129 funds tracked by Wall St. Rank held Nutex Health as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.